Participant flow

CT Antigen TCR-Engineered T Cells for Myeloma · Source last updated 2019-01-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants who received cytoreductive chemotherapy followed by infusion of lentivirus-mediated genetically engineered NY-ESO-1ᶜ²⁵⁹T (Target dose: 1-10 billion cells)

   id

   FG000

   title

   NY-ESO-1ᶜ²⁵⁹T Cells Administered IV

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Apheresed but not treated

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         6

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         2

      type

      Received T-cell

   3. achievements

      1. group Id

         FG000

         num Subjects

         2

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         4

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice